(Total Views: 362)
Posted On: 04/18/2022 4:29:29 PM
Post# of 30067
.jpg)
Item 4. Purpose of Transaction
“Item 4. Purpose of Transaction” is hereby supplemented as follows:
The Reporting Persons[Dominion], Anson Investments Master Fund LP and Lorient Ventures Ltd (collectively, the “Group”) have tentatively reached a satisfactory arrangement with the Issuer with respect to the issues discussed in the October 2020 Schedule 13D. On November 23, 2021, the Group and the Issuer entered into a term sheet (the “Term Sheet”) intended to resolve such issues. The Term Sheet contemplates resolution of such issues and outstanding claims to be covered in definitive agreements.
Item 7. Material to Be Filed as Exhibits
Exhibit 99.1 – Term Sheet, dated as of November 23, 2021, by and among Amarantus BioScience Holdings, Inc., Dominion Capital LLC, Anson Investments Master Fund LP, Lorient Ventures Ltd. and WilCarr Ventures.
“Item 4. Purpose of Transaction” is hereby supplemented as follows:
The Reporting Persons[Dominion], Anson Investments Master Fund LP and Lorient Ventures Ltd (collectively, the “Group”) have tentatively reached a satisfactory arrangement with the Issuer with respect to the issues discussed in the October 2020 Schedule 13D. On November 23, 2021, the Group and the Issuer entered into a term sheet (the “Term Sheet”) intended to resolve such issues. The Term Sheet contemplates resolution of such issues and outstanding claims to be covered in definitive agreements.
Item 7. Material to Be Filed as Exhibits
Exhibit 99.1 – Term Sheet, dated as of November 23, 2021, by and among Amarantus BioScience Holdings, Inc., Dominion Capital LLC, Anson Investments Master Fund LP, Lorient Ventures Ltd. and WilCarr Ventures.
(0)
(0)
